Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$7.09
−$0.36 · -4.83%
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Latest quote
$7.09
−$0.36 · -4.83%
After-hours
$7.23
+$0.14 · +1.97%
Sep 10, 4:29 PM ET
Regular session · ET · Market data may be delayed.
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Day range
Current $7.09
52-week range
Current $7.09
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
81
Deep Value
Sentiment
49
Mixed
Risk
58
Elevated Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Day range
Current $7.09
52-week range
Current $7.09
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 61.86M USD | 56.13M USD | 79.18M USD | 73.67M USD | 63.13M USD |
| Cost of goods sold | 25.18M USD | 20.88M USD | 26.66M USD | 30.78M USD | 32.08M USD |
| Gross profit | 36.68M USD | 35.26M USD | 52.52M USD | 42.89M USD | 31.05M USD |
| Research and development | 480K USD | 9.86M USD | 7.54M USD | 10.94M USD | 16.56M USD |
| Selling, general, and administrative | 44.37M USD | 40.2M USD | 43.91M USD | 59.47M USD | 39.83M USD |
| Operating expenses | 44.85M USD | 48.93M USD | 54.59M USD | 70.41M USD | 65.93M USD |
| Interest income | 589K USD | 757K USD | 322K USD | 60K USD | 2K USD |
| Interest expense | 3.7M USD | 2.7M USD | 1.7M USD | 2.02M USD | 7.03M USD |
| Depreciation and amortization | 4.35M USD | 3.52M USD | 3.86M USD | 4.37M USD | 2.56M USD |
| Operating income | −8.17M USD | −13.68M USD | −2.07M USD | −27.52M USD | −34.88M USD |
| Net income | −11.43M USD | −14.67M USD | −3.85M USD | −29.63M USD | −43.99M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3M0.00%2.3T USD0.03%$373.24-0.62%
Vanguard Extended Market ETFVXF1.19M0.00%93.7B USD0.05%$236.16-1.05%
iShares Micro-Cap ETFIWC376.94K0.03%1.49B USD0.60%$190.1-1.22%
Invesco NASDAQ Future Gen 200 ETFQQQS134.9K0.60%22.52M USD0.20%$42.6825-1.86%
U.S. Micro Cap Portfolio ETFDFMC24.91K0.00%7.73B USD0.43%$58.7359-0.78%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSU.S. Micro Cap Portfolio ETFDFMCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
